KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 5, 2010, Pages 456-460

  Gillern, Suzanne M ^a   Chua, Terence C ^b,c   Stojadinovic, Alexander ^a   Esquivel, Jesus ^a,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST AGNES HOSPITAL   (United States)

Author keywords

Colorectal cancer; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; KRAS mutations; Peritoneal carcinomatosis; Ras gene

Indexed keywords

ANTINEOPLASTIC AGENT; GENOMIC DNA; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WILD TYPE; CARCINOMA; COLORECTAL TUMOR; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; ONCOGENE RAS; PATHOLOGY; PERITONEUM TUMOR; SURVIVAL;

ADULT; AGED; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PERITONEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77956602320     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181b4b160     Document Type: Article

References (27)

1. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001;85:692-696.
2. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90:675-684.
3. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49: 4682-4689.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. New Engl J Med. 1988;319:525-532.
5. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the firstline treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 2008;26:5s.
6. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
7. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998;58:1149-1158.
8. Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol. 2001;19:299-304.
9. Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54:1283-1286
10. Pelz JO, Stojadinovic A, Nissan A, et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99:9-15.
11. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298-303.
12. Burmer GC, Loeb LA. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci USA. 1989;86:2403-2407.
13. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002; 101:403-408.
14. Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol. 2001;13:63-69.
15. Ward R, Meagher A, Tomlinson I, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 2001;48:821-829.
16. Hawkins NJ, Tomlinson I, Meagher A, et al. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer. 2001;84:232-236.
17. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13:1270-1275.
18. Etienne-Grimaldi M-C, Formento J-L, Francoual M, et al. K-ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14:4830-4835.
19. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer [comment]. New Engl J Med. 2009;360: 563-572.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med. 2004;350:2335-2342.
21. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-671.
22. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006 -2012.
23. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
24. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
25. D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007;14:759-765.
26. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14:1860-1869.
27. Chua TC. Gastrointestinal oncological surgery in patients with metastatic cancer treated with angiogenesis inhibitors: safe or not? ANZ J Surg. In press.